Abstract:Background: Clinical trials and animal studies have shown that sodium-glucose co-transporter type 2 (SGLT2) inhibitors improve pancreatic beta cell function. Our study aimed to investigate the effect of dapagliflozin on islet morphology and cell phenotype, and explore the origin and possible reason of the regenerated beta cells. Methods: Two diabetic mouse models, db/db mice and pancreatic alpha cell lineage-tracing (glucagon-beta-gal) mice whose diabetes was induced by high fat diet combined with streptozotocin, were used. Mice were treated by daily intragastric administration of dapagliflozin (1 mg/kg) or vehicle for 6 weeks. The plasma insulin, glucagon and glucagon-like peptide-1 (GLP-1) were determined by using ELISA. The evaluation of islet morphology and cell phenotype was performed with immunofluorescence. Primary rodent islets and alpha TC1.9, a mouse alpha cell line, were incubated with dapagliflozin (0.25-25 mu mol/L) or vehicle in the presence or absence of GLP-1 receptor antagonist for 24 h in regular or high glucose medium. The expression of specific markers and hormone levels were determined. Results: Treatment with dapagliflozin significantly decreased blood glucose in the two diabetic models and upregulated plasma insulin and GLP-1 levels in db/db mice. The dapagliflozin treatment increased islet and beta cell numbers in the two diabetic mice. The beta cell proliferation as indicated by C-peptide and BrdU double-positive cells was boosted by dapagliflozin. The alpha to beta cell conversion, as evaluated by glucagon and insulin double-positive cells and confirmed by using alpha cell lineage-tracing, was facilitated by dapagliflozin. After the dapagliflozin treatment, some insulin-positive cells were located in the duct compartment or even co-localized with duct cell markers, suggestive of duct-derived beta cell neogenesis. In cultured primary rodent islets and alpha TC1.9 cells, dapagliflozin upregulated the expression of pancreatic endocrine progenitor and beta cell specific markers (including Pdx1) under high glucose condition. Moreover, dapagliflozin upregulated the expression of Pcsk1 (which encodes prohormone convertase 1/3, an important enzyme for processing proglucagon to GLP-1), and increased GLP-1 content and secretion in alpha TC1.9 cells. Importantly, the dapagliflozin-induced upregulation of Pdx1 expression was attenuated by GLP-1 receptor antagonist. Conclusions: Except for glucose-lowering effect, dapagliflozin has extra protective effects on beta cells in type 2 diabetes. Dapagliflozin enhances beta cell self-replication, induces alpha to beta cell conversion, and promotes duct-derived beta cell neogenesis. The promoting effects of dapagliflozin on beta cell regeneration may be partially mediated via GLP-1 secreted from alpha cells. (C) 2020 The Author(s). Published by Elsevier Inc.

Pancreatic alpha cell glucagon–liver FGF21 axis regulates beta cell regeneration in a mouse model of type 2 diabetes

115-LB: Liver-Derived FGF21 Mediates the Promoting Effect of Glucagon Receptor Antagonism on Beta-Cell Regeneration in Type 2 Diabetic Mice

Glucagon Acting at the GLP-1 Receptor Contributes to β-Cell Regeneration Induced by Glucagon Receptor Antagonism in Diabetic Mice

Pro--cell-derived -cells contribute to -cell neogenesis induced by antagonistic glucagon receptor antibody in type 2 diabetic mice

Combination of GLP-1 Receptor Activation and Glucagon Blockage Promotes Pancreatic Β-Cell Regeneration in Situ in Type 1 Diabetic Mice

Antagonistic Glucagon Receptor Antibody Promotes Α-Cell Proliferation and Increases Β-Cell Mass in Diabetic Mice

Intra-islet glucagon signalling regulates beta-cell connectivity, first-phase insulin secretion and glucose homeostasis

Comments on ‘dietary Intervention Preserves Β Cell Function in Mice Through CTCF-mediated Transcriptional Reprogramming’

Glucagon Potentiates Insulin Secretion Via Beta-Cell Gcgr At Physiological Concentrations Of Glucose

P21cip-overexpression in the Mouse Beta Cells Leads to the Improved Recovery from Streptozotocin-Induced Diabetes.

Glucagon Switches between GLP-1 and Glucagon Receptors in Normal and Hyperglycemic Mice

Dapagliflozin Promotes Beta Cell Regeneration by Inducing Pancreatic Endocrine Cell Phenotype Conversion in Type 2 Diabetic Mice

Glucagon Potentiates Insulin Secretion Via β-Cell GCGR at Physiological Concentrations of Glucose

Exocrine pancreas regeneration modifies original pancreas to alleviate diabetes in mouse models

Pancreatic Beta Cell Regeneration Induced By Clinical And Preclinical Agents

Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling‐dependent manner

Targeted Pharmacological Therapy Restores Beta-Cell Function For Diabetes Remission

Γ-Aminobutyric Acid Modulates Α-Cell Hyperplasia but Not Β-Cell Regeneration Induced by Glucagon Receptor Antagonism in Type 1 Diabetic Mice

Glucagon receptor blockage inhibits ?-cell dedifferentiation through FoxO1

Ginseng extract improves pancreatic islet injury and promotes β-cell regeneration in T2DM mice

Glucagon Receptor Antagonism Promotes the Production of Gut Proglucagon-Derived Peptides in Diabetic Mice.